AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05846139 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PerioTabs® brushing solution
Description: PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
Study NCT05846139 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine 0.12 %
Description: chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
Study NCT06300216 — intervention group
Intervention type: DRUG
Intervention: Octreotide microspheres
Description: 20mg/30mg Q4W
Study NCT05315713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab SC
Description: Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
Study NCT05315713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
Study NCT05315713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
Study NCT05315713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
Study NCT04930874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS (Near-Infrared Spectroscopy)
Description: NIRS assessment of cerebral autoregulation and cerebral blood flow
Study NCT05198622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection
Description: A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery.
Study NCT05198622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection
Description: A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery.
Study NCT04815239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal and Social Rhythm Therapy (IPSRT)
Description: Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
Study NCT04815239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Healthy Lifestyle Behavior Intervention (HL)
Description: HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
Study NCT05143047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication counseling
Description: Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details.
Study NCT06056115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab,Platinum
Description: 1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy .
Study NCT05497063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine
Description: Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study NCT05336370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
Study NCT05336370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Description: A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
Study NCT05336370 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
Study NCT04510727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
Study NCT04510727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage & Desiccation (C&D) Procedure
Description: Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
Study NCT04861207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
Study NCT06354621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin-D supplementation
Description: Participants receiving a daily dose of vitamin D supplementation
Study NCT04745832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
Study NCT04745832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV 375 mg/m2 for 6 cycles
Study NCT04745832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
Study NCT04745832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
Study NCT06133010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile liquid for injection
Study NCT06133010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile liquid for injection
Study NCT05497063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-COSPE® tablets
Description: One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study NCT05780463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0420
Description: MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
Study NCT05780463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution
Study NCT05780463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study NCT05780463 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study NCT00012818 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: relaxation technique
Study NCT00012818 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational program
Study NCT04486066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
Study NCT04486066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Pain
Description: Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
Study NCT04486066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
Study NCT05657587 — intervention group
Intervention type: DEVICE
Intervention: SPRINT PNS
Description: Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
Study NCT05512650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Meditation
Description: Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
Study NCT05512650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-VR Meditation
Description: Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
Study NCT06559202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: chest and abdominoplevic CT
Description: chest and abdominopelvic computed tomography on the same day for health screening purposes
Study NCT06491797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate reactivation
Description: Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
Study NCT04925791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standardized pre-conditioning treatment
Description: 3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
Study NCT04925791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Partial occlusion
Description: 3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
Study NCT05739864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
Study NCT05739864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT
Description: This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
Study NCT06203444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: The study drug will be administered in dose of 50 mg bid
Study NCT06173362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given abiraterone
Study NCT06173362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06173362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given darolutamide
Study NCT06173362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given prednisone
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated Oxygen
Description: Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Concentrated Air
Description: Room air will be delivered through an concentrator provided via nasal cannula.
Study NCT04898205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Concentrated Air
Description: Room air will be delivered through an concentrator provided via nasal cannula.
Study NCT06152601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anticipated bipedal standing position in the immediate post-operative phase
Description: Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position.
Study NCT03575000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
Study NCT06334315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel / Ethinyl Estradiol Pill
Description: Standard pill packs containing 21 active pills and 7 placebo pills
Study NCT05858151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
Study NCT06322862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Indocyanine green
Description: Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
Study NCT05718518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC11 tablets
Description: Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)
Study NCT05718518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 and 2: Subjects will be randomized to receive placebo.
Study NCT05718518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV tablets
Description: Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)
Study NCT05899816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection
Study NCT05899816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection